De Witte Jan's Form 4/A amendment
AmendedResmed Inc (RMD) · filed May 22, 2024
- Accession no.
- 0001127602-24-016231
- Filed
- May 22, 2024
- Trade date
- May 15, 2024
- Filing delay
- 7 days
- Rule 10b5-1 plan
- Checked
- Original filed
- May 17, 2024
This filing lists 1 non-derivative transaction. Open-market sales total $78.6K. It was filed 7 days after the trade.
This amendment replaces 0001127602-24-015777 (filed May 17, 2024).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| De Witte JanCIK 0001776929 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 15, 2024 | ReMed Common Stock | SSaleDisposed | −360 | $218.29 | −$78,584.4 | 7,519 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Amended to indicate that the transaction was conducted under a Rule 10b5-1 plan adopted February 2, 2024.